A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE CLINICAL EFFICACY AND SAFETY OF BACTERIOPHAGES IN BACTERIAL INFECTIONS

Main Article Content

Authors

N.S. Sikhayeva ORCID

Joint stock company «National Holding «QazBioPharm», Korgalzhyn highway 13/5, Аstana, 010000, Kazakhstan

A.S. Dyussenbekova

Joint stock company «National Holding «QazBioPharm», Korgalzhyn highway 13/5, Аstana, 010000, Kazakhstan

K.B. Bekeshova

Joint stock company «National Holding «QazBioPharm», Korgalzhyn highway 13/5, Аstana, 010000, Kazakhstan

N.A. Esenbekova

Joint stock company «National Holding «QazBioPharm», Korgalzhyn highway 13/5, Аstana, 010000, Kazakhstan

Zh.D. Kanalyn

Joint stock company «National Holding «QazBioPharm», Korgalzhyn highway 13/5, Аstana, 010000, Kazakhstan

A.S. Rsaliyev ORCID

Joint stock company «National Holding «QazBioPharm», Korgalzhyn highway 13/5, Аstana, 010000, Kazakhstan

Y.O. Abduraimov ORCID

Joint stock company «National Holding «QazBioPharm», Korgalzhyn highway 13/5, Аstana, 010000, Kazakhstan

Abstract

The growing number of infections caused by multidrug-resistant bacteria (MDR) makes the development of alternative therapeutic strategies a priority of modern medicine. Bacteriophage therapy is considered as a promising method for the treatment of resistant infections; however, a systematic synthesis of clinical data remains an urgent task. The purpose of this review is to systematically summarize clinical data on bacteriophage therapy in humans and estimate the proportion of patients with clinical improvement.

A systematic search was performed in the PubMed/MEDLINE, Embase, and Cochrane CENTRAL databases (January 2000 - February 2026). Randomized controlled trials (RCTs), cohort studies, case series, and compassionate use studies with ≥3 participants were included. Primary outcome – percentage of patients with clinical improvement. The meta-analysis was performed using a random effects model (DerSimonian–Laird method, logit transformation, Hartung–Knapp correction). The risk of systematic error was assessed using the RoB 2 (for RCTs) and ROBINS-I (for non-randomized studies) instruments. The review was carried out in accordance with the PRISMA 2020 guidelines.

As a result, the final analysis included 17 studies (683 patients; 9 RCTs, 1 randomized uncontrolled study, and 7 nonrandomized studies) from more than 10 countries. The most studied pathogens were Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia coli. The pooled proportion of patients with clinical improvement was 57.2% (95% CI: 35.9–76.1%; k=8, N=393), with high heterogeneity (I²=88.2%; prediction interval: 10.7–93.7%). In the leave-one-out analysis, the pooled proportion ranged from 52.6% to 63.1%. The reviewed publications did not report any serious adverse events with a confirmed relationship to phage administration. Four RCTs had a low risk of bias.

In conclusion, published studies showed acceptable tolerability of bacteriophage therapy, with no reports of phage-related serious adverse events, and evidence suggestive of clinical benefit, particularly as an adjunct to antibiotic therapy for MDR infections. High heterogeneity, the predominance of uncontrolled study designs, and the noncomparative nature of the pooled estimate preclude conclusions about the efficacy of phage therapy relative to standard treatment. Large multicenter RCTs with standardized outcomes and systematic recording of adverse events are needed, along with standardization of the pharmaceutical quality of phage preparations.

Keywords

bacteriophage therapy, multidrug-resistant infections, systematic review, meta-analysis, clinical trials

Article Details

References

GBD 2021 Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. // Lancet. – 2024. – Vol. 404(10459). – P. 1199–1226. DOI: 10.1016/S0140-6736(24)01867-1. PMID: 39299261.

Suttle C.A. Marine viruses — major players in the global ecosystem. // Nat Rev Microbiol. – 2007. – Vol. 5(10). – P. 801–812. DOI: 10.1038/nrmicro1750. PMID: 17853907.

Gordillo Altamirano F.L., Barr J.J. Phage therapy in the postantibiotic era. // Clin Microbiol Rev. – 2019. – Vol. 32(2). – P. e00066-18. DOI: 10.1128/CMR.00066-18. PMID: 30651225.

Hatfull G.F., Dedrick R.M., Schooley R.T. Phage therapy for antibiotic-resistant bacterial infections. // Annu Rev Med. – 2022. – Vol. 73. – P. 197–211. DOI: 10.1146/annurev-med-080219-013420. PMID: 34428079.

Kim, M.K., Chen, Q., Echterhof, A. et al. A blueprint for broadly effective bacteriophage-antibiotic cocktails against bacterial infections. Nat Commun 15, 9987 (2024). PMID: 39609398 DOI: 10.1038/s41467-024-53994-9.

Skurnik, M., Alkalay-Oren, S., Boon, M. et al. Phage therapy. Nat Rev Methods Primers 5, 9 (2025). Crossref.

Luong, T., Salabarria, AC., Edwards, R.A. et al. Standardized bacteriophage purification for personalized phage therapy. Nat Protoc 15, 2867–2890 (2020). PMID: 32709990 DOI: 10.1038/s41596-020-0346-0.

Pirnay J.-P., Djebara S., Steurs G., Griselain J., Cochez C., De Soir S., Glonti T., Spiessens A., Vanden Berghe E., Green S., Wagemans J., Lood C., Schrevens E., Chanishvili N., Kutateladze M., de Jode M., Ceyssens P.-J., Draye J.-P., Verbeken G., De Vos D., Rose T., Onsea J., Van Nieuwenhuyse B., Soentjens P., Lavigne R., Merabishvili M. Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study. // Nat Microbiol. – 2024. – Vol. 9(6). – P. 1434–1453. DOI: 10.1038/s41564-024-01705-x. PMID: 37630602.

Teklemariam AD, Al Hindi R, Qadri I, Alharbi MG, Hashem AM, Alrefaei AA, Basamad NA, Haque S, Alamri T, Harakeh S. Phage cocktails - an emerging approach for the control of bacterial infection with major emphasis on foodborne pathogens. Biotechnol Genet Eng Rev. 2024 Apr;40(1):36-64. doi: 10.1080/02648725.2023.2178870. Epub 2023 Mar 17. PMID: 36927397.

Kim P., Sanchez A.M., Penke T.J.R., Tuson H.H., Kime J.C., McKee R.W., Slone W.L., Conley N.R., McMillan L.J., Prybol C.J., Garofolo P.M. Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial. // Lancet Infect Dis. – 2024. – Vol. 24(12). – P. 1319–1332. DOI: 10.1016/S1473-3099(24)00424-9. PMID: 39785652.

Adler, B.A., Hessler, T., Cress, B.F. et al. Broad-spectrum CRISPR-Cas13a enables efficient phage genome editing. Nat Microbiol 7, 1967–1979 (2022). Crossref. PMID: 36316451.

Zhang X, Zhang C, Liang C, Li B, Meng F, Ai Y. CRISPR-Cas9 Based Bacteriophage Genome Editing. Microbiol Spectr. 2022 Aug 31;10(4):e0082022. doi: 10.1128/spectrum.00820-22. Epub 2022 Jul 26. PMID: 35880867; PMCID: PMC9430736.

Song Zhang, Jin-Chul Kim, Juhee Ahn. Phage engineering strategies to expand host range for controlling antibiotic-resistant pathogens. Microbiological Research, Volume 300, 2025, 128278. PMID: 40652883 DOI: 10.1016/j.micres.2025.128278.

Page M.J., Moher D., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., Shamseer L., Tetzlaff J.M., Akl E.A., Brennan S.E., Chou R., Glanville J., Grimshaw J.M., Hróbjartsson A., Lalu M.M., Li T., Loder E.W., Mayo-Wilson E., McDonald S., McGuinness L.A., Stewart L.A., Thomas J., Tricco A.C., Welch V.A., Whiting P., McKenzie J.E. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. // BMJ. – 2021. – Vol. 372. – P. n160. PMID: 33782057.

Popay J., Roberts H., Sowden A., Petticrew M., Arai L., Rodgers M., Britten N., with Roen K., Duffy S. Guidance on the conduct of narrative synthesis in systematic reviews. // ESRC Methods Programme. – 2006.

McCallin S., Sarker S.A., Sultana S., Oechslin F., Brüssow H. Metagenome analysis of Russian and Georgian Pyophage cocktails and a placebo-controlled safety trial of single phage versus phage cocktail in healthy Staphylococcus aureus carriers. // Environ Microbiol. – 2018. – Vol. 20(9). – P. 3278–3293. DOI: 10.1111/1462-2920.14310. PMID: 29875132.

Chen W.H., Woolston J., Grant-Beurmann S., Robinson C.K., Bansal G., Nkeze J., Permala-Booth J., Fraser C.M., Tennant S.M., Shriver M.C., Pasetti M.F., Liang Y., Kotloff K.L., Sulakvelidze A., Schwartz J.A. Safety and tolerability of ShigActive™, a Shigella spp. targeting bacteriophage preparation, in a Phase 1 randomized, double-blind, controlled clinical trial. // Antibiotics. – 2024. – Vol. 13(9). – P. 858. DOI: 10.3390/antibiotics13090858. PMID: 37839985.

Jault P., Leclerc T., Jennes S., Pirnay J.P., Que Y.-A., Resch G., Rousseau A.F., Ravat F., Carsin H., Le Floch R., Schaal J.V., Soler C., Fevre C., Arnaud I., Bretaudeau L., Gabard J. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. // Lancet Infect Dis. – 2019. – Vol. 19(1). – P. 35–45. DOI: 10.1016/S1473-3099(18)30637-6. PMID: 30476261.

Weiner I., Kahan-Hanum M., Buchstab N., Zelcbuch L., Navok S., Sherman I., Nicenboim J., Axelrod T., Berko-Ashur D., Olshina M., Mordoch R., Jablonska J., Gera-Inbar T., Vainberg-Slutskin I., Blumenfeld B., Sberro-Livnat H., Moses A., Nevenzel H., Levy-Saar I., Gold J., Goldberg M., Tchernorudsky N., Ben-Yishay N., Cohen T., Kario E., Levovich I., Safonov R., Tzur Y., Zarchin Y., Lev V., Elharar Y., Safyon-Gartman E., Gahali-Sass I., Puttagunta S., Ussery X., Vilchez R., Rappo U., Zak N., Golembo M., Cohen A., Koff J., Kerem E., Sorek R., Bassan M. Phage therapy with nebulized cocktail BX004-A for chronic Pseudomonas aeruginosa infections in cystic fibrosis: a randomized first-in-human trial. // Nat Commun. – 2025. – Vol. 16. – P. 5579

Leitner L., Ujmajuridze A., Chanishvili N., Goderdzishvili M., Chkonia I., Rigvava S., Chkhotua A., Changashvili G., McCallin S., Schneider M.P., Liechti M.D., Mehnert U., Bachmann L.M., Sybesma W., Kessler T.M. Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial. // Lancet Infect Dis. – 2021. – Vol. 21(3). – P. 427–436. DOI: 10.1016/S1473-3099(20)30898-1. PMID: 33515302.

Verma V., Devi A., Jhunjhunwala B., Kumar R., Singh J., Pandey M.C., Patwa A. Evaluation of the safety and efficacy of Ganga Water-Phage Therapy plus standard medical therapy compared to standard medical therapy alone for Helicobacter pylori-related dyspepsia: a randomized controlled trial. // Cureus. – 2025. – Vol. 17(11). – P. e97383. DOI: 10.7759/cureus.97383. PMID: 38720077.

Bruttin A., Brüssow H. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. // Antimicrob Agents Chemother. – 2005. – Vol. 49(7). – P. 2874–2878. DOI: 10.1128/aac.49.7.2874-2878.2005. PMID: 15980313.

Nir-Paz R., Onallah H., Dekel M., Gellman Y.N., Haze A., Ben-Ami R., Braunstein R., Hazan R., Dror D., Oster Y., Cherniak M., Attal F., Barbosa A.R., Dordio H., Wagner A., Jones-Dias D., Neves J., Barreto M., Leandro C., Côrte-Real S., Garcia M. Randomized double-blind study on safety and tolerability of TP-102 phage cocktail in patients with infected and non-infected diabetic foot ulcers. // Med. – 2025. – Vol. 6(5). – P. 100565. DOI: 10.1016/j.medj.2025.100565

Samaee H.R., Eslami G., Rahimzadeh G., Saeedi M., Davoudi Badabi A., Asare-Addo K., Nokhodchi A., Roozbeh F., Moosazadeh M., Ghasemian R., Alikhani A., Rezai M.S. Inhalation phage therapy as a new approach to preventing secondary bacterial pneumonia in patients with moderate to severe COVID-19: a double-blind clinical trial study. // J Drug Deliv Sci Technol. – 2023. – Vol. 84. – P. 104486. DOI: 10.1016/j.jddst.2023.104486. PMID: 38013953.

Międzybrodzki R., Borysowski J., Weber-Dąbrowska B., Fortuna W., Letkiewicz S., Szufnarowski K., Pawełczyk Z., Rogóż P., Kłak M., Wojtasik E., Górski A. Clinical aspects of phage therapy. // Adv Virus Res. – 2012. – Vol. 83. – P. 73–121. DOI: 10.1016/B978-0-12-394438-2.00003-7.

Dedrick R.M., Smith B.E., Cristinziano M., Freeman K.G., Jacobs-Sera D., Belessis Y., Brown A.W., Cohen K.A., Davidson R.M., van Duin D., Gainey A., Berastegui Garcia C., George C.R.R., Haidar G., Ip W., Iredell J., Khatami A., Little J.S., Malmivaara K., McMullan B.J., Michalik D.E., Moscatelli A., Nick J.A., Tupayachi Ortiz M.G., Polenakovik H.M., Robinson P.D., Skurnik M., Solomon D.A., Soothill J., Spencer H., Wark P., Worth A., Schooley R.T., Benson C.A., Hatfull G.F. Phage therapy of Mycobacterium infections: compassionate use of phages in 20 patients with drug-resistant mycobacterial disease. // Clin Infect Dis. – 2023. – Vol. 76(1). – P. 103–112. DOI: 10.1093/cid/ciac453. PMID: 37405432.

Chan B.K., Stanley G.L., Kortright K.E., Vill A.C., Modak M., Ott I.M., Sun Y., Würstle S., Grun C.N., Kazmierczak B.I., Rajagopalan G., Harris Z.M., Britto C.J., Stewart J., Talwalkar J.S., Appell C.R., Chaudary N., Jagpal S.K., Jain R., Kanu A., Quon B.S., Reynolds J.M., Teneback C.C., Mai Q.-A., Shabanova V., Turner P.E., Koff J.L. Personalized inhaled bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis. // Nat Med. – 2025. – Vol. 31(5). – P. 1494–1501. DOI: 10.1038/s41591-025-03678-8.

Petrovic Fabijan A., Lin R.C.Y., Ho J., Maddocks S., Ben Zakour N.L., Iredell J.R. Safety of bacteriophage therapy in severe Staphylococcus aureus infection. // Nat Microbiol. – 2020. – Vol. 5. – P. 465–472. DOI: 10.1038/s41564-019-0634-z. PMID: 31944790.

Doub J.B., Johnson A.J., Nandi S., Ng V., Manson T., Lee M., Chan B.K. Experience using adjuvant bacteriophage therapy for the treatment of 10 recalcitrant periprosthetic joint infections: a case series. // Clin Infect Dis. – 2023. – Vol. 76(3). – P. e1463–e1466. DOI: 10.1093/cid/ciac694. PMID: 37274374.

Letkiewicz S., Łusiak-Szelachowska M., Międzybrodzki R., Zaczek M., Weber-Dąbrowska B., Górski A. Low immunogenicity of intravesical phage therapy for urogenitary tract infections. // Antibiotics. – 2021. – Vol. 10. – P. 627. DOI: 10.3390/antibiotics10060627. PMID: 34199570.

Aslam S. Bacteriophage therapy as a treatment option for transplant infections. // Curr Opin Infect Dis. – 2020. – Vol. 33(4). – P. 298–303. DOI: 10.1097/QCO.0000000000000658. PMID: 32657966.

Uyttebroek S., Merabishvili M., Pirnay J.-P., et al. Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review. // Lancet Infect Dis. – 2022. – Vol. 22. – P. e208–e220. DOI: 10.1016/S1473-3099(21)00612-5. PMID: 35248167.

Onallah H., Hazan R., Nir‑Paz R., et al. Compassionate use of bacteriophages for failed persistent infections during the first 5 years of the Israeli Phage Therapy Center. // Open Forum Infect Dis. – 2023. – Vol. 10(5). – Article ofad221. DOI: 10.1093/ofid/ofad221. PMID: 37234511.

Stacey H.J., De Soir S., Jones J.D. The safety and efficacy of phage therapy: a systematic review of clinical and safety trials. // Antibiotics. – 2022. – Vol. 11(10). – P. 1340. DOI: 10.3390/antibiotics11101340. PMID: 36289998.